Article Details
Retrieved on: 2024-11-04 21:12:42
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses Longeveron Inc.'s regenerative medicine efforts, including therapies for Alzheimer's disease. FDA designations, including Fast Track for Alzheimer's, enhance development prospects, aligning with tags like Pharmaceuticals policy and Regenerative biomedicine.
Article found on: finance.yahoo.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here